patients with newly diagnosed classical Hodgkin lymphoma (HL) have an excellent prognosis after multiagent chemotherapy with or without radiation. Biologic agents offer highly desirable approaches to patients with relapsed or refractory disease in which the
Search Results
Biologic Agents in the Management of Hodgkin Lymphoma
Armin Rashidi and Nancy L. Bartlett
Melanoma, Version 4.2014
Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho
reduce nodal relapse is a source of ongoing controversy because of the lack of survival benefits and concerns of late toxicities. With the advent of targeted therapy for advanced melanoma, there is increasing appreciation that the incidence of specific
Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes
H. Joachim Deeg and Marcos de Lima
-high-risk cytogenetics according to the revised IPSS-R criteria, have a very poor outcome after HCT, primarily related to relapse, which may occur in as many as 40% of patients. 26 This may be even more of an issue in older patients because of the use of RIC regimens
The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma
William I. Bensinger
the EBMT. European Group for Blood and Marrow Transplant . Br J Haematol 1998 ; 102 : 1115 – 1123 . 24 Corradini P Cavo M Lokhorst H . Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse
Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Philip L. McCarthy
: 825 – 831 . 4 Richardson PG Schlossman RL Weller E . Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma . Blood 2002 ; 100 : 3063 – 3067 . 5 Rajkumar SV
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Jane N. Winter, Joachim Yahalom, and Hema Sundar
drug conjugates (ADC) and monoclonal antibodies have shown promising results for patients with relapsed or progressive disease. 3 , 4 The following sections of these NCCN Guidelines Insights include the major discussion points from the 2011 Hodgkin
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, and Mallory Campbell
Cox regression analysis reported in the MRC UKALL XII/ECOG E2993 study, t(8;14), low hypodiploidy/near triploidy, and complex karyotype remained significant independent predictors for risk of relapse or death; the prognostic impact of these cytogenetic
Non-Hodgkin’s Lymphomas, Version 4.2014
Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar
(n=40; median age, 70 years), 50% were previously untreated, 93% had stage III/IV disease and 49% had high-risk MIPI scores. Patients with relapsed/refractory disease (n=20) had all previously received rituximab-containing therapies. 38 Among
Management of Multiple Myeloma
Shaji K. Kumar
's presentation covered the landscape of MM, from solitary bone lesions to smoldering disease to the primary treatment of active myeloma and relapsed disease. Solitary Plasmacytoma Solitary plasmacytomas—biopsy-proven solitary lesions of bone or soft
Hodgkin Lymphoma, Version 2.2015
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Hema Sundar
treatment and no treatment-related deaths or secondary leukemia were reported. Among 16 patients who experienced disease relapse, the freedom from second relapse was 69% at 5 years. Other investigators have also confirmed that the Stanford V regimen is
